Canopy Growth (CGC) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Canopy Growth (CGC) over the past year, gaining 97.6% versus a loss of 44.7%. Over five years, OBIO leads with a -41.8% price change compared with -99.4% for CGC. Canopy Growth is the larger company by market cap ($380.5 million vs $344.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | OBIO |
|---|---|---|
| Share price | $0.8468 | $5.73 |
| Market cap | $380.47M | $344.40M |
| 1-day change | -3.39% | +1.24% |
| YTD return | -25.72% | +38.07% |
| 1-year return | -44.65% | +97.59% |
| 5-year return | -99.37% | -41.83% |
| EPS (TTM) | $-0.45 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $6.50 |
| 52-week low | $0.81 | $2.86 |
| Distance from 52-week high | -64.42% | -11.85% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +41.71% | +116.93% |
| Average volume | 2.77M | 299.84K |
| Shares outstanding | 423.04M | 60.11M |
| Employees | 1,128 | 86 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed CGC by 142.2 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,128 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Healthcare · Biotechnology · 86 employees
CGC vs OBIO FAQ
Which is bigger, Canopy Growth or Orchestra BioMed?
Canopy Growth (CGC) is larger, with a market capitalization of $380.47M compared with $344.40M for Orchestra BioMed (OBIO).
Which stock has performed better over the past year, CGC or OBIO?
OBIO returned +97.59% over the past 12 months, compared with -44.65% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Orchestra BioMed in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Canopy Growth and Biotechnology for Orchestra BioMed.